|
|
|
|
||
|
||
|
Vol. 8, Nos. 1-50 pp. 1-1650 Jan. 1 - Dec. 31, 2010 A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
ULTRACET
– Painkiller patent, generic settlement (D.N.J.), 747
– Pain drug patent obviousness (Fed. Cir.), 743
– AstraZeneca transfers pricing settlement, 293
– Prostate drug patent, generic infringes (D. Del.), 642; patent upheld, 1106
– Biosimilar meetings, 1560
– Expiration FDA authority, 357 – Ezogabine, 1161 – FY2008 collections, 629 – FY2011 FDA budget proposal, 164; hearings, 327; fee hike, 1024 – Generics, planned FDA meeting, 1058; preparing negotiations, 1150; quicker approvals, 1224; reopened comment period, 1434 – PDUFA goals, FDA progress, 560 – Reauthorization, industry support, 493 – Small business waiver suit dismissal (N.D. Ill.), 183 – Tropical disease drugs, 1228 – 2010 FDA agenda, 630
– Antipsychotics and diabetes (Utah Dist. Ct.), 623
– Medicaid
– – Avandia suit (Utah Dist. Ct.), 1466
– – AWP suit dismissal (Utah Dist. Ct.), 271 Contact the Webmaster at webmaster@bna.com Copyright © The Bureau of National Affairs, Inc. All Rights Reserved. |
